期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.731947
关键词
regulatory T cell; autoimmune disease; cancer; tolerance; immunotherapy
类别
资金
- Hellenic Foundation for Research and Innovation (H.F.R.I)
- Stavros Niarchos Foundation (S.N.F) [166]
- European Research Council (ERC) under the European Union [947975]
- Hellenic Foundation for Research and Innovation (H.F.R.I.) [166]
- [1429]
- European Research Council (ERC) [947975] Funding Source: European Research Council (ERC)
Treg cell plasticity plays a significant role in autoimmunity and cancer, characterized by loss of Foxp3 expression. It has great therapeutic potential through destabilizing Treg cells to promote anti-tumor immunity or enhancing Treg cell stability to attenuate chronic inflammation.
Regulatory T (Treg) cells, possess a strategic role in the maintenance of immune homeostasis, and their function has been closely linked to development of diverse pathologies including autoimmunity and cancer. Comprehensive studies in various disease contexts revealed an increased plasticity as a characteristic of Treg cells. Although Treg cell plasticity comes in various flavors, the major categories enclose the loss of Foxp3 expression, which is the master regulator of Treg cell lineage, giving rise to ex-Treg cells and the fragile Treg cells in which FOXP3 expression is retained but accompanied by the engagement of an inflammatory program and attenuation of the suppressive activity. Treg cell plasticity possess a tremendous therapeutic potential either by inducing Treg cell de-stabilization to promote anti-tumor immunity, or re-enforcing Treg cell stability to attenuate chronic inflammation. Herein, we review the literature on the Treg cell plasticity with lessons learned in autoimmunity and cancer and discuss challenges and open questions with potential therapeutic implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据